Cenix BioScience and collaborators awarded major research grant from German National Genome Research Network (NGFN) for development of anti-malarial agents.
 

Dresden, Germany, January 6, 2005  - Cenix BioScience GmbH today announced that it, along with several consortium partners, has secured grant support under the German National Genome Research Network (NGFN) program, financed by the German Federal Ministry of Education and Research (BMBF).

As part of the network grant entitled "SMP-RNAi: Methodological Platform for Studies of Gene Functions from Cells to the Entire Organism", Cenix will be collaborating with the National Research Center for Environment and Health (GSF) in Munich, the German Cancer Research Center (DKFZ) and the European Molecular Biology Laboratory (EMBL) in Heidelberg, the Max Planck Institute for Cell Biology and Genetics (MPI-CBG) in Dresden, and the Max Planck Institute for Molecular Genetics (MPI-MG) in Berlin. Over the coming two years, Cenix will be awarded a total of 584,000 Euro, serving as the central provider of RNAi services within the consortium, exploring novel silencing reagents and alternative cell-based transfection approaches, and standardizing newly developed application protocols, including data annotation.